



NIH PUBLIC ACCESS

Author Manuscript

Org Lett. Author manuscript; available in PMC 2013 May 04.

Published in final edited form as:


Org Lett. 2012 May 4; 14(9): 2366–2369. doi:10.1021/ol300785c.

## Enantioselective Synthesis of the C1-C6 and C7-C23 Fragments of the Proposed Structure of Iriomoteolide 1a

Michael T. Crimmins\* and Anne-Marie R. Dechert

Kenan, Caudill, Venable and Murray Laboratories of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

### Abstract



Synthesis of the C1-C6 and C7-C23 fragments of the proposed structure of iriomoteolide 1a has been accomplished. Key steps include a cross metathesis to form the C15-C16 *E* olefin and a chelation controlled Grignard addition to form the tertiary alcohol at C14. Notably, 7 of the 9 stereocenters of the proposed structure have been set using various aldol reactions employing metallo enolates of thiazolidinethiones.

In 2007, Tsuda and coworkers isolated a novel macrolide from the dinoflagellate *sp.* *Amphidinium* strain HYA024, identified as iriomoteolide 1a (**1**).<sup>1</sup> The natural product exhibits potent cytotoxicity against the human B lymphocyte DG-75 cells ( $IC_{50} = 0.002$  mg/mL), which is 20 times more potent than doxorubicin ( $IC_{50} = 0.04$  mg/mL), a common chemotherapy agent.<sup>1</sup> Additionally, iriomoteolide 1a also displays activity against Epstein-Barr virus (EBV) infected human B-lymphocyte Raji cells ( $IC_{50} = 0.003$  mg/mL).<sup>1</sup> Because of the attractive biological profile and the unique structural attributes of iriomoteolide 1a, several laboratories have undertaken the total synthesis of **1**. The groups of Loh,<sup>2</sup> Paterson,<sup>3</sup> Zhao,<sup>4</sup> Li,<sup>5</sup> and Dai<sup>6</sup> have reported creative approaches to complex fragments of **1**, while Horne,<sup>7</sup> Ghosh,<sup>8</sup> and Yang<sup>9</sup> have completed the total synthesis of macrolactone **1**. During the course of their synthetic studies, Horne,<sup>7</sup> Ghosh,<sup>8</sup> and Yang<sup>9</sup> independently ascertained that the proposed structure of iriomoteolide 1a had been misassigned.

Our interest in the total synthesis of iriomoteolide 1a stems from the inherent ability of the thiazolidinethione chiral auxiliary to access all possible polyketide subunits using simple variations of aldol reaction conditions. Once a convergent route to the proposed structure is developed, appropriate diastereomers can be rapidly prepared in a highly convergent fashion in an effort to elucidate the actual structure of the natural product. The retrosynthetic analysis is shown in Figure 2. It was envisioned that iriomoteolide 1a would arise via a late stage Yamaguchi esterification<sup>10</sup> between acid **2** and secondary alcohol **3** followed by a ring closing metathesis to construct the C6-C7 alkene and install the macrocyclic ring of **1**. A

crimmins@email.unc.edu.

Supporting Information Available Experimental details and spectral data for new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

cross metathesis of enone **4** with PMB ether **5** would form the C15-C16 *E* olefin, while a nonselective aldol between a C12-C23 methyl ketone and aldehyde **6** would assemble the C11-C12 bond.

Preparation of the C16-C23 PMB ether **5** commenced with an Evans *syn* aldol with thioimide **7** and acetaldehyde to provide the secondary alcohol **8** in 80% yield and 20:1 dr (Scheme 1).<sup>11</sup> Protection of the secondary alcohol as the TIPS ether and cleavage of the chiral auxiliary delivered a primary alcohol, which underwent a one-carbon homologation by first transforming the primary alcohol into mesylate **9** followed by stirring with KCN. Isolation of the nitrile proved difficult, so the crude mixture was reduced directly with *i*-Bu<sub>2</sub>AlH, to provide aldehyde **10**. Aldehyde **10** was then subjected to a second Evans *syn* aldol with thioimide **11**, generating secondary alcohol **12** in 86% and >20:1 dr.<sup>12</sup> Reductive cleavage of the chiral auxiliary with LiBH<sub>4</sub> provided a diol, which cleanly underwent an acetal formation-reduction sequence to regioselectively mask the secondary alcohol as PMB ether **13**. Exposure of the resultant primary alcohol to mesyl chloride followed by LiEt<sub>3</sub>BH reduction generated PMB ether **5** in 12 steps and 18% overall yield.

The C12-C15 fragment was synthesized beginning with commercially available (*S*)-ethyl lactate, which was transformed in two steps via a known procedure to the benzyl protected Weinreb amide **14** (Scheme 2).<sup>13</sup> Exposure of Weinreb amide **14** to excess vinyl Grignard reagent provided **4** (Figure 2), which was utilized in a cross metathesis with PMB ether **5** to deliver exclusive formation of the *E* isomer **15** in 67% yield over 2 steps. A chelation-controlled addition of methyl magnesium bromide to ketone **15** provided the tertiary alcohol **16** as the only detectable diastereomer after reductive cleavage of the benzyl ether with lithium 4,4-di-*t*-butylbiphenylide (LDBB).<sup>14</sup> Oxidation of the secondary alcohol to the ketone under Parikh-Doering conditions<sup>15</sup> produced the ketone **17a**. Protection of the tertiary alcohol as its TBS ether provided the C12-C23 fragment **17b**. The stereochemistry of the tertiary alcohol at C14 was deduced by forming the 5-membered acetonide **18** from diol **16** (Scheme 3). The C14 stereochemistry was assigned as (*R*) based on observed NOESY correlation between the C13 hydrogen and C14 methyl group as well as C15 hydrogen and the C13 methyl group.

With ketone fragment **17a** in hand, attention turned to preparation of aldehyde **6**. Beginning with an acetate aldol utilizing mesityl substituted thiazolidinethione **19**<sup>16</sup> and 3-butenal,<sup>17</sup> secondary alcohol **20** was generated in 70% yield and >20:1 dr (Scheme 4). Protection of the resulting secondary alcohol as the TES ether, and reductive cleavage of the chiral auxiliary furnished aldehyde **6**. A nonselective aldol between ketone **17a** and aldehyde **6** delivered the secondary alcohol as an inconsequential ca. 1:1 mixture of diastereomers at C11.

Cleavage of the TES ether and spontaneous ketalization to form a mixed methyl ketal was accomplished under mild conditions utilizing catalytic triphenyl phosphonium hydrobromide salt to deliver an unstable mixed methyl ketal.<sup>18</sup> The resultant alcohol was used directly in the subsequent Ley oxidation<sup>19</sup> to afford ketone **21**. The C11 exocyclic methylene proved challenging to install: attempts to install the C11 exocyclic olefin under standard methylenation conditions (Wittig, Tebbe,<sup>20</sup> Tour,<sup>21</sup> Takai-Nozaki<sup>22</sup>) in the presence of the free tertiary alcohol at C14 (**21**) resulted in either elimination or no reaction, likely due to the presence of the free alcohol at C14. Attempts to protect the free alcohol of **21** directly with TESOTf, TMSOTf, or TMSCl resulted in formation of the C11 mixed silyl ketal, wherein the silyl triflate or silyl chloride behaved as Lewis acids due to the crowded steric environment, rather than silylating agents as in similar systems.<sup>23</sup> Fortunately, the C14 tertiary alcohol of **17a** could be protected as the TBS ether prior to the aldol addition to form **17b**. Aldol reaction of ketone **17b** and aldehyde **6** followed by treatment as before generated mixed ketal **22**. The exocyclic methylene was then successfully installed in 77% yield

employing the Tebbe reagent.<sup>20</sup> Cleavage of the PMB ether was accomplished with DDQ, which also cleaved the mixed methyl ketal to deliver hemiketal **3**.

Synthesis of the C1-C6 fragment **2** began with a known Evans *anti* aldol with thioimide **23** and cinnamaldehyde<sup>24</sup> followed by a Hoveyda-Grubbs catalyzed ethylene cross metathesis to install terminal olefin **24** (Scheme 5). Protection of the secondary alcohol as the TBS ether and cleavage of the chiral auxiliary afforded aldehyde **25**, which was subjected to a Corey-Fuchs homologation<sup>25</sup> to deliver ynoate **26**. Methyl cuprate addition was used to form enoate **27**, and the olefin geometry was confirmed by observed NOESY correlations between the C2 hydrogen and C3 methyl group. Cleavage of the methyl ester to the acid was accomplished with LiOH and MeOH to provide acid **2** in 63% yield over 2 steps. Completion of the synthesis of **1** would require esterification of acid **2** with alcohol **3**, protection of the silyl ethers followed by RCM to generate the proposed structure of iriomoteolide 1a, in a similar strategy to that employed by Horne.<sup>7</sup>

In summary, a concise and convergent approach to the proposed structure of iriomoteolide 1a has been developed. Key steps include a cross metathesis to form the C15-C16 bond, and an acetate aldol to form the C21-C-22 bond. The thiazolidinethione chiral auxiliary was exploited to create 7 of the 9 stereocenters of iriomoteolide 1a through various aldol additions. Importantly, simple changes in the reagents utilized in these aldol additions can facilitate access to other possible stereoisomers. Since the proposed structure of the natural product has been incorrectly assigned, our current efforts are directed toward utilizing our approach to prepare diastereomers of the reported structure in an effort to elucidate the correct structure of the natural product.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

Financial support from the National Institute of General Medical Sciences (GM60567) is gratefully acknowledged.


## References

1. Tsuda M, Oguchi K, Iwamoto R, Kobayashi J, Fukushi E, Kawabata J, Ozawa T, Masuda A, Kitaya Y, Omasa K. *J Org Chem.* 2007; 72:4469. [PubMed: 17500570]
2. (a) Chin Y, Wang S, Loh T. *Org Lett.* 2009; 11:3674. [PubMed: 19627100] (b) Wang S, Chin Y, Loh T. *Synthesis.* 2009:3557.
3. Patterson I, Rubenbauer P. *Synlett.* 2010:571.
4. Ye Z, Deng L, Quian S, Zhao G. *Synlett.* 2009:2469.
5. Li S, Cheng Z, Xu Z, Ye T. *Chem Commun.* 2010; 46:4773.
6. Liu Y, Wang J, Li H, Wu J, Feng G, Dai W. *Synlett.* 2010:2184.
7. (a) Xie J, Ma Y, Horne D. *Chem Commun.* 2010; 46:4770. (b) Xie J, Ma Y, Horne DA. *Org Lett.* 2009; 11:5082. [PubMed: 19799392] (c) Xie J, Horne DA. *Tetrahedron Lett.* 2009; 50:4485.
8. (a) Ghosh AK, Yuan H. *Org Lett.* 2010; 12:3120. [PubMed: 20560539] (b) Ghosh AK, Yuan H. *Tetrahedron Lett.* 2009; 50:1416. [PubMed: 20948581]
9. (a) Fang L, Yang J, Yang F. *Org Lett.* 2010; 12:3124. [PubMed: 20560543] (b) Fang L, Xue H, Yang J. *Org Lett.* 2008; 10:4495.
10. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. *Bull Chem Soc Jpn.* 1979; 52:1989.
11. (a) Crimmins MT, Chaudhary K. *Org Lett.* 2000; 2:775. [PubMed: 10754681] (b) Crimmins MT, King BW, Tabet EA, Chaudhary K. *J Org Chem.* 2001; 66:894. [PubMed: 11430110] (c) Crimmins MT, She J. *Synlett.* 2004:1371.


12. (a) Crimmins MT, Slade DJ. *Org Lett.* 2006; 8:2191. [PubMed: 16671814] (b) Crimmins MT, Dechert AMR. *Org Lett.* 2009; 11:1635. [PubMed: 19281219]
13. (a) Itso Y, Kobayashi Y, Kawabata T, Takase M, Terashima S. *Tetrahedron.* 1989; 45:5767. (b) Tomooka K, Kikuchi M, Igawa K, Suzuki M, Keong PH, Nakai T. *Angew Chem Int Ed.* 2000; 39:4502. (c) Shang S, Iwandare H, Macks DE, Ambrosin LM, Tan DS. *Org Lett.* 2007; 9:1895. [PubMed: 17439132]
14. (a) Freeman PK, Hutchinson LL. *J Org Chem.* 1980; 45:1924. (b) Ireland RE, Smith MG. *J Am Chem Soc.* 1988; 110:854.
15. Parikh JR, Doering WE. *J Am Chem Soc.* 1967; 89:5505.
16. Crimmins MT, Shamszad M. *Org Lett.* 2007; 9:149. [PubMed: 17192107]
17. Crimmins MT, Kirincich SJ, Wells AJ, Choy AL. *Synth Commun.* 1998; 28:3675.
18. Smith AB, Fox RJ, Vanecko JA. *Org Lett.* 2005; 7:3099. [PubMed: 15987215]
19. Ley SV, Norman J, Griffith WP, Marsden SP. *Synthesis.* 1994:639.
20. (a) Pine SH, Zahler R, Evans DA, Grubbs RH. *J Am Chem Soc.* 1980; 102:3270. (b) Tebbe FN, Parshall GW, Reddy GS. *J Am Chem Soc.* 1978; 100:3611.
21. Tour JM, Bedworth PV, Wu R. *Tetrahedron Lett.* 1989; 30:3927.
22. Takai K, Hotta Y, Oshima K, Nozaki H. *Tetrahedron Lett.* 1978; 19:2417. Hibino JI, Okazoe T, Takai K, Nozaki H. *Tetrahedron Lett.* 1985; 26:5579. Okazoe T, Hibino JI, Takai K, Nozaki H. *Tetrahedron Lett.* 1985; 26:5581.
23. (a) Braje W, Frackenpohl J, Langer P, Hoffman HMR. *Tetrahedron.* 1998; 54:3495. (b) Chrobok A, Gossinger E, Kalb R, Orglmeister E, Schwaiger J. *Tetrahedron.* 2007; 63:8326.
24. Evans DA, Downey CW, Shaw JT, Tedrow JS. *Org Lett.* 2002; 4:1127. [PubMed: 11922799]
25. Corey EJ, Fuchs PL. *Tetrahedron Lett.* 1972; 13:3.




**Figure 1.**  
Iriomoteolide 1a proposed structure.




**Figure 2.**  
Retrosynthetic analysis of iriomoteolide 1a.

**Scheme 1.**Preparation of the C<sub>16</sub>-C<sub>23</sub> fragment of iriomoteolide 1a.




**Scheme 2.**  
 Synthesis of the C<sub>12</sub>-C<sub>23</sub> fragment **17**.






**Scheme 3.**  
Stereochemical proof for the absolute stereochemistry of the C<sub>14</sub> tertiary alcohol.



**Scheme 4.**  
Preparation of the C<sub>7</sub>-C<sub>23</sub> fragment **3**.



**Scheme 5.**  
Preparation of the C<sub>1</sub>-C<sub>6</sub> fragment **2** and proposed completion of **1**.